Intellia Therapeutics (NTLA) concentration risks

The company's disclosed concentration is a high-share, dual-program pipeline dependency at the late-stage clinical level. The two lead assets — lonvo-z, being developed for hereditary angioedema (HAE) and targeted for commercial launch in the first half of 2027, and nex-z, being evaluated for ATTR amyloidosis — are both in Phase 3 development,. The character of both exposures is mixed: the concentration reflects the strategic focus typical of clinical-stage companies, but the advancement to Phase 3 introduces meaningful regulatory and execution risk on both programs simultaneously. The nex-z program carries an incremental idiosyncratic risk: the FDA placed a clinical hold on the MAGNITUDE and MAGNITUDE-2 Phase 3 trials following a patient dosing event, adding regulatory uncertainty that is specific to this program rather than a market-wide headwind. A hold extension, protocol redesign requirement, or adverse safety signal could delay or derail the nex-z program independently of lonvo-z's trajectory. Lonvo-z is positioned as the nearer-term revenue catalyst, with a planned launch in the first half of 2027. Together, the concentration in these two programs means the investment outcome is heavily levered to clinical and regulatory execution across both. There is no commercial revenue base, approved product, or material pipeline diversification disclosed that would cushion results against a setback in either asset.

For the engine’s reasoning on NTLA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.